The prostate cancer section is a comprehensive resource for urology news and expert insights. Read more at Urology Times.

Low-intensity extracorporeal shock wave therapy is a safe treatment for men with erectile dysfunction and might work to improve, or even cure, ED in some patients. But there remain important ...

Bicycle modifications can potentially improve genitourinary outcomes after cycling. For example, in our cohort, cyclists who stood more than 20% of the time while cycling and adjusted the handlebar to ...

In this interview, Mark C. Markowski, MD, PhD, discusses bipolar androgen therapy (BAT), including its advantages and disadvantages, trials that have evaluated the treatment, and what some next steps ...

Bladder cancer is the 10th most common cancer worldwide with an estimated 82,000 new diagnoses and 17,000 deaths in 2023. 1 The majority of patients present with non–muscle invasive bladder cancer ...

Using the PhalloFILL system, a novel hyaluronic acid filler, appeared to be safe when administered for penile girth enhancement, according to a retrospective review presented at the 24th Annual Fall ...

In this interview, Mohit Khera, MD, MBA, MPH, shares insights on the use of testosterone replacement therapy in men with prostate cancer, touching on current evidence and also stressing the importance ...

Key Takeaways Anktiva is the first drug to rescue T and NK cells, crucial for cancer cell eradication and memory generation. The "triangle offense" involves NK cells, CD8 killer T cells, and memory T ...

On July 10, 2024, the Centers for Medicare & Medicaid Services (CMS) released the Calendar Year (CY) 2025 Medicare Physician Fee Schedule Proposed Rule. It outlines CMS’ proposed updates for payments ...

Specifically, the bill cuts funding for CDMRP from $1.509 billion in FY2024 to $650 million in FY2025. Prostate and kidney cancer research is currently funded at $110 million and $50 million, ...

Dr Hamstra describes the three FDA-approved rectal spacers SpaceOAR, Barrigel, and BioProtect, noting differences in placement technique, advantages, potential risks, and the need for long-term ...

Key Takeaways mCSPC and mHSPC refer to prostate cancer with metastases that remain responsive to hormone therapy, often used interchangeably. Both conditions involve the presence of metastases and ...